Achieve Life Sciences, Inc. (ACHV) stock
ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
$6.61+0.23 (+3.53%)
Close on Oct 19, 2026Market cap $679.67MP/E –Yield –
Achieve Life Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Achieve Life Sciences's free cash flow for the twelve months ending Dec 31, 2023 was -$24.50M. For fiscal 2025 it was -$49.47M. The highest annual figure on record is $34.86M in fiscal 2009.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.47M | – |
| FY2023 | Dec 31, 2023 | -$24.50M | – |
| FY2020 | Dec 31, 2020 | -$13.49M | – |
| FY2019 | Dec 31, 2019 | -$15.27M | – |
| FY2018 | Dec 31, 2018 | -$10.67M | – |
| FY2016 | Dec 31, 2016 | -$248.00K | – |
| FY2015 | Dec 31, 2015 | -$721.00K | – |
| FY2014 | Dec 31, 2014 | -$17.39M | – |
| FY2013 | Dec 31, 2013 | -$36.18M | – |
| FY2012 | Dec 31, 2012 | -$43.78M | – |
| FY2011 | Dec 31, 2011 | -$20.34M | – |
| FY2010 | Dec 31, 2010 | -$26.91M | -177.2% |
| FY2009 | Dec 31, 2009 | $34.86M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$4.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.42M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.07M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.94M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.98M | -119.5% |
| Q2 FY2017 | Jun 30, 2017 | -$18.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$69.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $15.30M | – |
See a number that looks wrong?